Brief: Oncocyte Corp Says Oncocyte's Vitagraft Kidney Transplant Diagnostic Test Receives CMS Coverage
28/08/2023 21:35
Aug 28 (Reuters) - OncoCyte Corp OCX.O :
* ONCOCYTE CORP - ONCOCYTE'S VITAGRAFT KIDNEY TRANSPLANT
DIAGNOSTIC TEST RECEIVES CMS COVERAGE
Source text for Eikon: ID:
Further company coverage: OCX.O
((Reuters.Brief@thomsonreuters.com;))
Recent news on Insight Molecular Diagnostics
See all newsBrief: Insight Molecular Diagnostics Enters Amendment No. 2 To Merger Agreement On Sept 15, 2026
Insight Molecular Diagnostics Inc reports results for the quarter ended June 30 - Earnings Summary
Insight Molecular Diagnostics Inc expected to post a loss of 24 cents a share - Earnings Preview
Insight Molecular Diagnostics Q1 loss narrows as costs drop
Brief: Insight Molecular Diagnostics Completes Key Milestones Advancing Graftassuredx Toward FDA Submission